Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FGJBT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
P38B-DM1
|
|||||
| Synonyms |
P38B DM1; P38B DBCO-HSA-DM-1
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Melanoma [ICD11:2C30]
Investigative
Squamous cell cancer [ICD11:2D60-2D61]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.9
|
|||||
| Antibody Name |
P38B
|
Antibody Info | ||||
| Antigen Name |
Podoplanin (PDPN)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Azide-modified dibenzocyclooctyne(DBCO)-albumin(HAS)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines (Lys 248).
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 75
|
%
|
CHO cells (PDPN expression)
|
Melanoma
|
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 75.00% (Day 18) | Positive PDPN expression (PDPN +++/++) | ||
| Method Description |
One day after cell inoculation, 100 mg of antibodies (P38B-DM1, P38B, or normal canine IgG) in 100 mL of PBS were injected into the peritoneal cavity of each mouse. On days 8 and 14, 5 mg/kg P38B-DM1 was injected into each mouse.
|
||||
| In Vivo Model | CHO/dPDPN CDX model | ||||
| In Vitro Model | Melanoma | CHO cells (PDPN expression) | CVCL_0213 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 48.00 ng/mL | Positive PDPN expression (PDPN +++/++) | ||
| Method Description |
0.01-10 mg/mL for 30 minutes, followed by treatment with fluorescein isothiocyanate-conjugated.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.09 nM | High HER2 expression (HER2+++) | ||
| Method Description |
0.01-10 mg/mL for 30 minutes, followed by treatment with fluorescein isothiocyanate-conjugated.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.12 nM | High HER2 expression (HER2+++) | ||
| Method Description |
0.01-10 mg/mL for 30 minutes, followed by treatment with fluorescein isothiocyanate-conjugated.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.78 nM | High HER2 expression (HER2+++) | ||
| Method Description |
0.01-10 mg/mL for 30 minutes, followed by treatment with fluorescein isothiocyanate-conjugated.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 35.00 nM | High HER2 expression (HER2+++) | ||
| Method Description |
0.01-10 mg/mL for 30 minutes, followed by treatment with fluorescein isothiocyanate-conjugated.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 97.62 nM | Low HER2 expression (HER2+) | ||
| Method Description |
0.01-10 mg/mL for 30 minutes, followed by treatment with fluorescein isothiocyanate-conjugated.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 110.54 nM | Low HER2 expression (HER2+) | ||
| Method Description |
0.01-10 mg/mL for 30 minutes, followed by treatment with fluorescein isothiocyanate-conjugated.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.